These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35174593)

  • 1. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study.
    Li Y; Lu J; Chen R; Wang Y; Ding Y; Xu S; Zou Y; Yi X; Shi Y
    Dermatol Ther; 2022 May; 35(5):e15385. PubMed ID: 35174593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
    Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
    JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
    Gu C; Wu Y; Luo Y; Wang S; Yin H; Gao Y; Wang C; Yao X; Li W
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1064-1073. PubMed ID: 35344634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
    Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
    Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
    Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
    Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.
    Pagan AD; David E; Ungar B; Ghalili S; He H; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2378-2385. PubMed ID: 35753667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
    Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
    Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
    Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab.
    Martinez-Cabriales S; Marcoux D; Liy-Wong C; Prajapati VH; Sibbald C; Cunningham N; Lansang P; Tonkin R; Joseph M; Wong L; Spring S; Gavigan G; Ramien M
    Pediatr Dermatol; 2024; 41(1):5-11. PubMed ID: 37906120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study.
    Berna-Rico E; Fiz-Benito E; Busto-Leis JM; Servera-Negre G; de Lucas-Laguna R; Feito-Rodriguez M
    Dermatology; 2024; 240(2):337-342. PubMed ID: 38035567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
    Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
    J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.